Impact of bridging with perioperative low-molecular-weight heparin on cardiac and bleeding outcomes of stented patients undergoing non-cardiac surgery

Summary

When patients with coronary stents undergo non-cardiac surgery, bridging therapy with low-molecular-weight heparin (LMWH) is not infrequent in clinical practice. However, the efficacy and safety of this approach is poorly understood. This was a retrospective analysis of patients with coronary stent(s) on any antiplatelet therapy undergoing non-cardiac surgery between March 2003 and February 2012. The primary efficacy endpoint was the 30-day incidence of major adverse cardiac or cerebrovascular events (MACCE), defined as the composite of cardiac death, myocardial infarction, acute coronary syndrome leading to hospitalisation, or stroke. The primary safety endpoint was the 30-day composite of Bleeding Academic Research Consortium (BARC) bleedings ≥ 2. Among 515 patients qualifying for the analysis, LMWH bridging was used in 251 (49 %). At 30 days, MACCE occurred more frequently in patients who received LMWH (7.2 % vs 1.1 %, p=0.001), driven by a higher rate of myocardial infarction (4.8 % vs 0 %, p< 0.001). This finding was consistent across several instances of statistical adjustment and after the propensity matching of 179 pairs. Patients bridged with LMWH also experienced a significantly higher risk of BARC bleedings ≥ 2 (21.9 % vs 11.7 %, p=0.002) compared to those who were not, which remained significant across different methods of statistical adjustment and propensity matching. In conclusion, LMWH bridging in patients with coronary stents undergoing surgery is a common and possibly harmful practice, resulting in worse ischaemic outcomes at 30 days, and a significant risk of bleeding.

Keywords

Stent thrombosis - noncardiac surgery - heparin

• References

• 1 Capodanno D, Angiolillo DJ. Management of antiplatelet therapy in patients with coronary artery disease requiring cardiac and non-cardiac surgery. Circulation 2013; 128: 2785-2798.
• 2 Berger PB, Kleiman NS, Pencina MJ. et al. Frequency of major non-cardiac surgery and subsequent adverse events in the year after drug-eluting stent placement results from the EVENT (Evaluation of Drug-Eluting Stents and Ischaemic Events) Registry. JACC Cardiovasc Interv 2010; 03: 920-927.
• 3 Wijeysundera DN, Wijeysundera HC, Yun L. et al. Risk of elective major non-cardiac surgery after coronary stent insertion: a population-based study. Circulation 2012; 126: 1355-1362.
• 4 Rossini R, Musumeci G, Capodanno D. et al. Perioperative management of oral antiplatelet therapy and clinical outcomes in coronary stent patients undergoing surgery. Results of a multicentre registry. Thromb Haemost 2015; 113: 272-282.
• 5 Mehran R, Rao SV, Bhatt DL. et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 2011; 123: 2736-2747.
• 6 Ndrepepa G, Schuster T, Hadamitzky M. et al. Validation of the Bleeding Academic Research Consortium definition of bleeding in patients with coronary artery disease undergoing percutaneous coronary intervention. Circulation 2012; 125: 1424-1431.
• 7 Jneid H, Anderson JL, Wright RS. et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 Guideline and replacing the 2011 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2012; 60: 645e681.
• 8 Cutlip DE, Windecker S, Mehran R. et al. Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007; 115: 2344-2351.
• 9 Kopp VJ. Use of the American Society of Anesthesiologists Physical Status Classification System in research. Anesth Analg 2013; 117: 752.
• 10 Fleisher LA, Fleischmann KE, Auerbach AD. et al. 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Non-cardiac Surgery: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 64: e77-e137.
• 11 Kristensen SD, Knuuti J, Saraste A. et al. 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur Heart J 2014; 35: 2383-2431.
• 12 Hawn MT, Graham LA, Richman JS. et al. Risk of major adverse cardiac events following non-cardiac surgery in patients with coronary stents. J Am Med Assoc 2013; 310: 1462-1472.
• 13 Wijeysundera DN, Wijeysundera HC, Yun L. et al. Risk of elective major non-cardiac surgery after coronary stent insertion: a population-based study. Circulation 2012; 126: 1355-1362.
• 14 Mehran R, Baber U, Steg PG. et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet 2013; 382: 1714-1722.
• 15 Rossini R, Musumeci G, Visconti LO. et al. Perioperative management of anti-platelet therapy in patients with coronary stents undergoing cardiac and non-cardiac surgery: a consensus document from Italian cardiological, surgical and anaesthesiological societies. EuroIntervention 2014; 10: 38-46.
• 16 Broad L, Lee T, Conroy M. et al. Successful management of patients with a drug-eluting coronary stent presenting for elective, non-cardiac surgery. Br J Anaesth 2007; 98: 19-22.
• 17 Vicenzi MN, Meislitzer T, Heitzinger B. et al. Coronary artery stenting and non-cardiac surgery-a prospective outcome study. Br J Anaesth 2006; 96: 686-693.
• 18 Mauri L, Kereiakes DJ, Yeh RW. et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014; 371: 2155-2166.
• 19 Mehran R, Pocock SJ, Stone GW. et al. Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. Eur Heart J 2009; 30: 1457-1466.
• 20 Musumeci G, Rossini R, Lettieri C. et al. Prognostic implications of early and long-term bleeding events in patients on one-year dual antiplatelet therapy following drug-eluting stent implantation. Catheter Cardiovasc Interv 2012; 80: 395-405.
• 21 Rao SV, Ohman EM. Anticoagulant therapy for percutaneous coronary intervention. Circ Cardiovasc Interv 2010; 03: 80-88.
• 22 Angiolillo DJ, Firstenberg MS, Price MJ. et al. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. J Am Med Assoc 2012; 307: 265-274.